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Summary 
Predictive modeling plays a key role in providing more accurate prognosis and enables us to take 
a step closer to personalized treatment. We identified two potential sources of human induced 
biases that can evidently lead to disparate conclusions. We illustrate through a rather complex 
phenotype that robust results can still be drawn after accounting for such biases. 
 
Often predictive models build based in high dimensional data suffers from the drawback of lack 
of interpretability. To achieve interpretability in the form of description of the organism level 
phenomena in term of molecular or cellular level activities, functional and pathway information 
is often augmented. Functional information can greatly facilitate the interpretation of the results 
of the predictive model.  
 
However an important aspect of (vertical) data augmentation is routinely ignored, that is there 
could be several stages of analysis where such information could be meaningfully integrated. 
There is no know criteria to enable us to assess the effect of such augmentation. A novel aspect 
of the proposed work is in exploring possibilities of stages of analysis where functional 
information may be incorporated and in assessing the extent to which the ultimate conclusions 
would differ depending on level of amalgamation. 
 
In order to boost our confidence on the key biological findings a first level of meta-analysis is 
carried out by exploring different levels of data augmentation. This is followed by comparison of 
predictive models across different definitions of the same phenotype developed by different 
groups, which is also an extended form of meta-analysis. 
 
We have used real life data on a complex phenotype to illustrate the above. The data pertains to 
Chronic Fatigue Syndrome (CFS) and another novel aspect of the current work is in modeling 
the underlying continuous symptom measurements for CFS, which is the first for this disease to 
our knowledge.    
 
Keywords: Phenotype prediction, functional data, supervised-PCA, cross validation, meta-
analysis, Chronic fatigue syndrome. 
1. Introduction 
In this exercise consider predictive model building for continuous phenotype based on 
genomic data. Such models often become difficult to interpret in the biological context thus 
common practice is to augment functional information. However we routinely fail to realize that 
there could be several alternate steps in the model building effort where such information can be 
utilized and as can be expected ultimate functional interpretation could and does depend on 
where such data was incorporated. Our objective would be to explore whether robustness of final 
findings can be achieved when faced with such alternate choices of integrating same data. Apart 
from the continuous nature of the phenotype that we target to model and predict, clinical 
complexity of such phenotypes also mean alternate definition of measurement methods for such 
phenotypes. Common experience is that prominent biological pathways identified behind such 
phenotype depend on how the phenotype was defined. 
Thus we have identified three issues that have emerged as key challenges in carrying out 
reproducible research in this field. First and foremost is in realizing that model fit is not enough, 
in order to bring benefits to larger population more efforts must be put in predictive model 
building. With sufficient degree of complexity a model might fit data in hand perfectly but might 
be far from satisfactory when it comes to predicting unseen (i.e. outside the sample) data.  
Secondly, with the wealth of availability of data, routinely data is to augment from various 
sources. As in horizontal data integration one can consider multiple type of useful data, similarly 
for vertical data integration often there are multiple stages in the analysis pipeline where one 
might amalgamate such information. For horizontal data integration it is customary to report 
findings based on different data sources however rarely it is investigated how robust are the final 
findings in view of alternate methods of vertical data augmentation.  
Third aspect we would like to draw attention to is that of phenotype definition which plays 
highly critical role for complex diseases. Many diseases/syndromes occur in multitude of clinical 
symptoms leading to multiple ways of defining them. Once again a relevant issue would be to 
assess the impact of alternate definitions of the phenotype on our conclusions. Here our effort 
would be in providing a solution that will enable us identify predictors of complex phenotypes 
that would be robust against both alternate choices of data integration and alternate definitions of 
phenotype. 
With the increasing availability of high dimensional (genomic) data on subjects, it has 
become essential to device techniques to relate such high-dimensional genetic or genomic data to 
various (clinical) phenotypes of patients. Modeling and/or analysis of high dimensional data, 
(e.g. genome-scale genetic data, genomic/transcriptomic data, new-generation sequencing data, 
etc,) has received great attention for more than a decade. However only recently predictive 
model building based on high throughput data has gained momentum. Recent focus of research 
in this area is from the urge to bring benefits of advanced research from bench to bedside and 
provide personalized deductions from models.  
High dimensional data generates a common problem to both model fitting and predictive 
model building efforts, which is to identify key variables. As the name suggests data from high-
throughput techniques are often quite large in size, thus initially substantial effort might have to 
be put in to derive usable/interpretable variables. Depending on the technology used to capture 
the covariate information the explanatory data could be binary (genotype data), discrete (e.g. 
sequence information), continuous (inclusive but not limited to gene expression). Irrespective of 
the type of experimental data the end model still might not be readily interpretable.  
It is possible to derive biologically meaningful covariates based on the original ones that 
are also smaller in number. External knowledge from databases like Gene Ontology (Ashburner 
et al., 2000) has been used by Chen (2008), from KEGG (Kanehisa et al., 2008) by Li and Li 
(2008). Further work on this can be found in Binder & Schumacher (2009) and Pan et al. (2010). 
Thus a step towards easier interpretability would be to use such functional data. We attempt to 
augment additional knowledge from existing databases, in particular the Gene Ontology 
database, to provide better interpretability of such models.  
However even if we identify some specific source of data to amalgamate, there might still 
be multiple stages in the analysis pipeline where such data can be augmented meaningfully. Our 
experience of decades of data analyses of real data has taught us that the results based on 
different ways of data integration often leads to different biological results. We investigated 
effects of such alternate manners of data augmentation and propose a consensus method to arrive 
at robust conclusions. To the best of our knowledge this has not been attempted before (even for 
model fitting, let alone for predictive model building). 
Predictive modeling has reasonable literature when the response variable is dichotomous/ 
categorical in nature, where primarily methods for classification are employed/extended. 
Classification is a relatively easier problem, since as long as the conclusion is on the correct side 
of cut-off, a decision is considered to be correct and the margin of correctness is deemed 
irrelevant. Thus for same problem it is not surprising to achieve considerable accuracy in 
classification, say 70-80%, whereas when prediction of the continuous phenotype is attempted, 
association measure between predicted and observed quantities might be rather small ranging 
0.10-0.20 (on the scale from -1 to +1) (see Bhattacharjee 2013, Bøvelstad & Borgan 2011). Thus 
for ease of analysis and/or ease of interpretation often the underlying response is recoded into 
categories. However such categorization of the continuous phenotype leads to loss of 
information, additionally many situations require dealing with the actual phenotype in its 
continuous form.  
An additional layer of complicacy noticed for complex phenotypes is varied 
manners/definitions in which they can be described. Often these diseases manifest in a range of 
symptoms and consequently there could be multiple ways of gathering information and 
quantification, as we will see in the real life example used for illustration here (see also Haibe--
Kains et al Nature, 2013, for an example from pharmacogenomics). 
In this work we will explore meta-analytic approaches for vertical data integration which 
enables robust prediction of phenotypes. The proposed concepts will be illustrated by 
probabilistic modeling of real life data on complex phenotypes and augmented of high 
throughput data. We would use a well-known data set on chronic fatigue syndrome (CFS). For 
79 individuals binary classifications of individuals according to CFS and otherwise were 
proposed by Reeves et al. (2005). So far this is the most commonly analyzed phenotype data for 
CFS based on this data. However it is the (continuous) symptom scores that were measured 
originally. Our objective is to build predictive models based on genomic data with additional 
data augmented from the Gene Ontology database.  
2. Materials and methods 
2.1 Data 
The gene expression data and the CFS symptom scores used in here were made available 
during the CAMDA 2006 and CAMDA 2007 conferences. The data pertains to self-administered 
questionnaires filled in by 227 subjects from whom blood samples were drawn subsequently for 
laboratory analysis.  
Subject recruitment, clinical evaluation, laboratory tests and their classification were 
described previously (Reeves et al 2005). As reported therein, 227 subjects were recruited from 
Wichita, Kansas, USA as part of a two-day in-hospital evaluation of unexplained fatigue. During 
the two-day hospital stay, symptoms and exclusionary medical and psychiatric conditions were 
re-evaluated for all 227 subjects. Following the two-day hospital study, all subjects were 
classified based on all aspects specified in 1994 CFS case definition (Fukuda 1994). The 
symptom information was recorded according to the Medical Outcomes Short-Form (SF36), 
Multi-Dimensional-Fatigue Inventory (MDF) and Center for Disease Control (CDC) Symptom 
Inventory. The symptoms include measures on the functional impairment, fatigue and 
accompanying symptom complex that characterize CFS.  
Following this classification, 124 subjects were excluded because of medical or psychiatric 
exclusionary conditions or insufficient criteria to classify as CFS. Usable microarray data were 
available for 79 of the 103 remaining subjects. Based on earlier work of Reeves et al (2005) 
these 79 individuals can be classified as CFS (39 subjects) and non-fatigued (NF, 40 subjects). 
The demographic characteristics along with type of disease onset (gradual vs. sudden) of subjects 
in this study are given in Table 1. We note from this table that the two groups of patients (viz. 
CFS and NF) appear similar with respect to the distributions of several important relevant 
factors, like age, gender, BMI etc. Thus this eliminates possibility of confounding factors 
affecting the conclusions of our analyses. 
However since degree of affect of the disease on a subject vary substantially thus it would 
be an over simplification to dichotomize the disease status,. Even worse there are phenotypes, 
like CFS, which could be hard to even define and are without any clinical indicators that can 
confirm the presence of the disease. Therefore unlike previous studies where only the CFS and 
NF characterization of subjects have been used, in this study we would like to target modeling 
the underlying disease score.  
Further complications arise in regard to diseases like CFS where there are alternate 
opinions as to how to capture the severity/effect of this disease on a subject. We have used three 
prominent notions of quantifying this disease, namely, SF36, MDF and CDC symptom inventory 
mentioned above. 
Direct aggregation method is employed to derive the symptom scores for both SF-36 and 
MDF methods. For CDC Symptom Inventory was used, methods recommended by Wagner et al 
(2005) was used. In this methods the presence of a symptom along with its frequency and 
severity were used (multiplicatively) to yield individual symptom level score and these scores 
were then added to obtain the combined symptom score for each subject. Further details are 
available in the supplementary materials. The score based on CDC symptom inventory can be 
further subdivided into the two categories, viz. directly related to CFS and otherwise relevant. 
Table -2 contains the symptoms covered under each of these methods of defining CFS. 
As mentioned above, our objective here would be to model and predict the symptom scores 
and not the dichotomized disease status (which is more commonly done). Given the complexity 
of a disease like CFS and the diversity of symptoms in which it manifests, one would expect it 
would be natural to consider an appropriate measure for this disease than denoting people as 
having the disease or not. Our literature search revealed only one another work which comes 
close to this objective (Smith et al. 2009).  
Figure 1 presents some descriptive summary of these symptom scores. As can be seen none 
of three prominent phenotype measures, viz. the Total-score, SF36 and MDF corresponds to 
clear relationship with the binary phenotype status. The CFS related score however has nearly 
distinct distributional behavior for the CFS and NF individuals, based on the current data set. 
As mentioned in the introduction, interpretation of predictive models is a challenging job. 
It is even more so for a complex disease like CFS where the symptoms are diverse and 
overlapping with many other diseases. Thus additional knowledge on the covariates could shed 
light into the effects and interpretations of the predictors (along with their effect estimates) on to 
the response variable. There are few well-known data bases that contain information of 
biological processes, molecular functions of genomic entities, e.g. Gene Ontology, KEGG 
databases. We would utilize functional information on the genes from the Gene Ontology 
database (Ashburner et al. 2000), which has larger coverage in terms of number of genes. This 
information can be utilized at different levels of modeling, where one can start with expression 
profiles of biological functions instead of individual gene expressions as predictors, also on the 
other hand one can follow up the influence of the biological profiles at the end of gene 
expression based predictive modeling. 
2.2 Analysis Methods 
Using gene expression data with various choices of predictive models (e.g. Multiple 
Regression, Generalized Linear Model, Cox-proportional hazard model, etc) and variable 
selection techniques (e.g. supervised PCA, LASSO, ridge regression) have been reported in 
Bhattacharjee (2013). It appears that the choice of variable selection technique seems to have 
greater effect on the prediction quality than the predictive model itself (similar findings were 
reported for other data by Bovelsatd et al (2011).  
Also let’s remind ourselves that our objective here is for a given phenotype to arrive at a 
consensus set of (biologically interpretable) predictors taking into account known variabilities 
like data augmentation choices and phenotype definitions. If we further introduce widely 
different modeling techniques, which potentially optimize different characteristics, then it is 
unlikely we would reach such a consensus.  
For our data related to CFS the SPCA seemed to perform the better than the other models. 
Note that we do not restrict to the use of first principal component only. To quote from Paul et al 
(2008), “Typically, we use just the first or first few supervised principal components”. It appears 
unfortunately in many applications people pay attention to only half of that recommendation. 
Most data that we analyzed required many more than “first” PC to achieve reasonable 
performance. Additionally unlike Chen (2008) instead of fixing number of PCs, a range of 
number of PCs was explored. For each such choice additionally various thresholds as cutoff for 
correlation in the supervised stage of the SPCA were used. This resulted in over 1000 models 
being explored for each choice of data augmentation method and definition of phenotype.  
Following SPCA based dimension reduction we implemented multiple regression based 
predictive modeling. The optimal tuning parameters are to be determined based on a 5-fold 
cross-validation. Therefore methods used to analyze the data sets in this paper are (i) principal 
component analysis (PCA), (ii) supervised principal component analysis (SPCA), (iii) linear 
models and (iv) cross-validation. Further details on each of these have been provided in the 
supplementary material.  
2.3 Functional data incorporation  
In the context of CFS, attempting to use Gene Ontology (GO) data (Ashburner et al. 2000) 
is not a novel idea. Emmert-Streib (2007) used 12 pathways and their expressions to make 
predictions about the modification of pathways due to pathogenesis. However given the diverse 
symptom manifestation of CFS, it is a long foregone conclusion that possibility of characterizing 
CFS by handful of genes or functions is futile. We are also not attempting to identify or order 
key pathways or biological functions as in Chen et al. (2008), thus it allows us to use as many 
functional categories relevant for the disease as necessary.  
Thus retaining as much of the relevant ontology information as possible, we propose the 
first model where using the entire gene expression matrix and corresponding mapping of 
functions, functional level expressions are estimated. These pathway level expressions are used 
as predictors in SPCS and subsequent predictive models, denoted as Model-1: “GO-start” 
(indicating GO information being used from the very start of analysis). 
Chen et al. (2008) proposed a method for assessing significant association of gene-
ontology defined sets of genes with continuous outcomes. They used the screening/variable 
selection step of the SPCA method first before utilizing the Gene ontology information. This is 
because the entire set of genes related to a particular biological function would be affected by 
variation unrelated to outcome. 
Our objective here is to produce predictive model as accurate as possible which would also 
enable us to carry out interpretations simultaneously. Thus in a spirit similar to that proposed by 
Chen et al (2008) we consider a model where the Gene ontology information would be used only 
on the selected set of genes that are screened through the supervised step of the SPCA. Since the 
GO information is utilized midway in the analysis pipeline we would refer this second model as 
Model-2: “GO-mid”.  
Lastly we propose to use the more commonly used approach of using gene –expressions 
for deriving the predictive model and then following up with interpretation using functional 
information. In this set up the SPCA and predictive modeling is carried out using the gene level 
expression values and only at the end stage of analysis functional information is incorporated / 
projected on to the genes (or their effects on the phenotypes). We would refer to this model as 
Model 3: “GO-end”. 
Interestingly both in Model-1 and Model-3 gene ontology information on all genes are 
used (either in building the predictive model or in subsequent interpretation). However in Model-
2 since a subset of genes is selected (for each fold and each threshold value) the GO information 
on these genes is used in the subsequent analysis and interpretation. 
In the following we present a flow-diagram depicting the analysis pipeline under different 
modeling strategy proposed by us (Figure-2). 
3. Results 
In all modeling efforts 5-fold cross-validation was carried out. In each step of analysis we 
ensured that information from the learning/training set is not leaked into test set. For example the 
supervised step wherein key variables are selected based on their relevance is carried out based 
on data on subject from learning set only. Thus often 5-fold cross validation leads to 5 possibly 
different lists of variables. This error can and is common to occur unintentionally in many 
analyses (see Bair 2004 for an example). 
As mentioned above for each phenotype, each choice of GO data incorporation level and 
each fold, more than 1000 models were applied. For every model using the predictive values for 
the test data predictive correlations were obtained. We used these to compare performances of 
different models. For each of the three types of GO-input method and four types of phenotype, 
the model with highest correlation with the phenotype was deemed to be the best model.  
To identify relative key GO terms the fold level coefficients estimates were consolidated  
for each GO term using average. This method could be applied for GO-Start and GO-Mid data 
augmentation techniques. Once again the absolute coefficients for GO-terms were used to 
measure their effects on a predictive model. 
However GO-End produces coefficients at gene level and further mapping between genes 
and GO-terms were used to derive GO-term level coefficient. This however leads to only 
marginal estimates for GO-terms and not joint estimates as obtained under GO-Start and GO-
mid. Thus in further analyses of identification of GO terms GO-End results were not included 
due to lack of compatibility. 
We observed that the best performing model thus identified may not be consistent across 
phenotypes and even GO-input method in terms of coefficients of the GO-terms. Thus instead of 
restricting ourselves to top few models and top few functions, we assessed the consistency of 
effect estimates for all GO-functions considered here across all 1026 models under each 
modeling scenario and each of four phenotypes. In most cases although the top performing 
models may not correlate highly, we could identify models with similar predictive performance 
and also exhibiting high association with models for other phenotypes/GO-input method. In 
Table-3 we presented results for the best model and a closely performing alternate model. The 
predictive correlation measure for model performance and also pair wise association measures 
bewteen these 16 models are presented therein. Note that results from GO-End strategy have 
been omitted due to compatibility issues mentioned earlier. 
We can further reduce these selected 16 models with one model for each phenotype while 
still preserving reasonable prediction performance quality. In table-4 we present the 
performance, pair wise similarity of GO-coefficients and concurrence of GO-terms in top 20% 
(in absolute magnitude) in the predictive models. This indicates that not only a large set of 
functionalities appear to be common under these models but their manner of affecting the 
phenotype is also very similar. 
Most of these models are relatively sparse and although we considered the top 20%  
coefficients based on absolute magnitude (i.e. 156 functions), the effective number of non-zero 
coefficients could be even less. We could identify 69 GO-based biological functions that 
consistently showed up across all four phenotype definitions, two data augmentation methods 
and in terms of their high relevance in predicting the respective phenotype. We present such a 
list in Table-5.  
We will reiterate that objective of this exercise was not necessarily to derive the optimal 
modeling strategy for predicting this particular instead illustrate a method to account for some 
known but often ignored sources of variation. However there is still a need to produce some 
assessment whether the predictive qualities achieved here were of any significance or not.  
Unfortunately to the best of our knowledge there is no previous record of modeling this 
disease in continuous phenotype form. Thus whether the performances of the top models are 
adequate or not would require some alternate means of investigation. We return our focus to the 
relatively more studies binary representation of the phenotype. One possibility would be to use 
cut-off on the estimated phenotype values to conclude about the binary disease status. However 
we have to recognize that it would be futile to try and implement that strategy for each of the 
four phenotypes. Thus we used the phenoype-1 which is based on "All-symptoms" from the 
CDC-symptom inventory, which is the natural choice given both the binary and this particular 
continues measure were proposed by same group. It should be mentioned here that even when 
the true knowledge on the continuous phenotypes is available, they do not accurately identify the 
underlying dichotomized disease status. The accuracy of phenotype-1 based on CDC's "All-
symptom" is 93.7% where as that using "CFS-related symptoms" is 98.7%.  
However it is also possible to carry out similar modeling strategy can be extended to the 
binary phenotype also, by implementing SPCA and Generalized Linear Models, where the 
predictive model is changed to reflect the binary nature of the response function. As before the 
GO data incorporation can be carried out at various stages. 
The results are presented in Table-6 where we notice that even a crude threshold based 
method (on the continuous prediction) can produce comparable or even better performance than 
modeling the binary phenotype itself. 
The earlier work on such prediction of CFS status based on similar data can found in 
Bassetti et al.(2006). They report average classification accuracy of 77% on 130 patients using 
K-means clustering. Given that our focus here has been to estimate the harder problem of 
continuous phenotype and estimation of binary disease status is only of secondary interest, where 
the continuous outcome in truth also does not clearly identify the binary classes, we feel it will 
not be unreasonable to believe that the above performance (in Table-6) is quite encouraging. We 
need to keep in mind that these are results of out-of-sample prediction and not measures of 
model fit (of data at hand). 
As has been reported in Bhattacharjee (2013) prediction of the continuous phenotype using 
the gene level expression measurements (and without functional data) reaches correlations about 
0.4 using similar modeling strategy. By using threshold method on these predictions an accuracy 
of 71% can be achieved for the binary phenotype, which is less or comparable to the accuracies 
achieved here. 
Thus if one would wonder if there has been any noticeable deterioration in performance of 
the predictive model by amalgamating the gene level information to functional level summaries, 
one would be happy to conclude that neither prediction of the continuous phenotype nor 
accuracy of prediction of the binary phenotype has been compromised in any way. We should 
keep in mind that the predictive modeling frameworks have been maintained at comparable level 
across all these analyses (i.e. use of SPCA and GLM). 
4. Discussion  
Proposed work has several novel aspects, first being those relevant to the specific disease 
chosen here, namely CFS. Although is CFS is measured using symptom severities, nearly all 
modeling efforts use dichotomized version of these, thus losing information and also subjective 
dichotomization leading to lack of inter study comparability. As mentioned before to the best of 
our knowledge this is the first known effort to model the Chronic Fatigue Syndrome on a 
continuous scale of measurement. We attempted to model the underlying continuous disease 
measure for Chronic Fatigue Syndrome, instead of using the dichotomized phenotype. This 
evidently makes it harder but when compared with approximate accuracy rate of the binary 
phenotype prediction, the results of continuous phenotype prediction appear encouraging. 
Additionally the model being predictive provides information on not just the data at hand but 
also similar unseen data sets. 
A more general and novel applicability of our method is that we have identified and 
rectified against two potential artificial sources of bias often introduced in the analyses by the 
researchers. The first is in recognizing that functional information can greatly facilitate the 
interpretation of the results of the (predictive) model. However there is no know criteria to 
enable us to assess the effect of such augmentation. As we have shown through the lack of 
consistency among the "Best" models that each such method can very well lead to completely 
dispersed conclusions in identifying key predictors (as noted by poor or even negative 
correlations in table-3).    
Often it is the researcher and not the biological context that determines which method for 
data augmentation would be used. We have explored possibilities of stages of analysis where 
functional information may be incorporated and also assessed whether the ultimate conclusions 
would differ depending on level of amalgamation. We have shown that with little or no 
compromise in model performance the difference strategies of incorporating GO data we could 
identify consistent conclusions, even for an well known complex phenotype like the one 
considered here. 
Accurate phenotype definition is key to reproducibility, as is well understood by now. 
However complex phenotypes like CFS manifests in a gamete of symptoms and once again it is 
the researcher who decides and uses specific definition of his/her choice. It is then not surprising 
the conclusions differ from study to study as we illustrated once again (in Table-3) that even 
using exactly same modeling framework we might very well make diverse conclusions regarding 
the key network/biological players. This too can be avoided and common factors identified 
through consensus method as carried out here may lead to better understanding of the phenotype. 
As for extension of the current work, we noticed from figure-1 that it is likely that the 
underlying phenotype distributions are asymmetric and has longer right tails. A method to model 
this would be in changing the predictive model from linear model to generalized linear model 
(e.g. by using a Gamma distribution for response). However although in theory the method 
should work in practice because of the very nature of this data the standard computational 
procedure of IRWLS (i.e Iteratively Re-weighted Least Squares) method to obtain the estimates 
for such a Gamma response model often fail in practice. This it would be worth to investigate in 
future how to overcome such computational difficulties in modeling with other distributions 
from the exponential family. A second aspect would be of course to use multiple experimental 
data, that could help reduce effect of sampling bias in the conclusions. It is rather phenotype 
specific whether multiple such data sets with stuitable information of genomic and phenotypic 
data would be available.  
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FIGURE LEGENDS 
 
Figure 1:  Box-plots of the four different types of symptom score according to dichotomized 
symptom score of NF (non-fatigued) and CFS patients.  
 
Figure 2: Schematic diagram of analysis flow chart where gene ontology information is 
incorporated at different level of analysis yielding different model.  
 Figure 1 
 Figure 2 
Table 1: Demographic and other relevant characteristics of the subjects selected for analysis. 
Factor Categories NF subjects (n=40) CFS subjects (n=39) 
Age (years) MQMQMa 31 / 43.8 / 50.5 / 53.3 / 69 34 / 47 / 53 / 58.5 / 69 
Sex (n) Female/Male 31 / 9 32 / 7 
Race(n) White/Black/Others 36 / 2 / 2 36 / 1 / 2 
  
  
BMI MQMQMa 20 / 26 / 29 / 31.3 / 40 23 / 26 / 29 / 31.5 / 40 
Onsetb Gradual/ Sudden 13 / 1 35 / 3 
aMQMQM represents the minimum, first quartile, median, third quartile and maximum 
respectively. 
bOnset represents gradual vs sudden onset of illness. This information is available for all but one 
CFS subject. For NF subjects, onset information is relevant to only 14 individuals with past 
report of chronic fatigue.  
 
Table 2: Symptoms from CDC inventory to derive the two continuous phenotype measures 
related to CFS, namely CFS-score and Total-score. 
CDC symptom inventory Medical Outcomes Survey 
Short-Form (SF-36) 
Multidimensional 
Fatigue Inventory 
(MFI) 
CFS related symptoms Symptoms otherwise 
relevant to CFS 
1. Post Exertion 
Fatigue  
2. Un-refreshing Sleep 
3. Memory 
4. Concentration 
5. Muscle Pain 
6. Joint Pain 
7. Sore Throat 
8. Tender Nodes 
9. Headache 
 
1. Diarrhea 
2. Fever 
3. Chills 
4. Sleep Problems 
5. Nausea 
6. Abdominal Pain 
7. Sinus Nasal 
8. Shortness of 
breath 
9. Photophobia 
10. Depression 
 
1. Limitations in physical 
activities because of 
health problems 
2. Limitations in social 
activities because of 
physical or emotional 
problems 
3. Limitations in usual 
role activities because 
of physical health 
problems 
4. Bodily pain 
5. General mental health 
6. Limitations in usual 
role activities because 
of emotional problems 
7. Vitality (energy and 
fatigue) 
8. General health 
perceptions 
1. General Fatigue 
2. Physical Fatigue 
3. Mental Fatigue 
4. Reduced 
Motivation  
5. Reduced Activity 
  
 
Table 3: Correlations between estimated coefficients for all 781 GO functions for top 
performing and alternate models under different modeling methods and phenotypes. 
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1.00 0.98 0.04 0.92 0.04 0.97 0.54 0.92 0.02 0.79 0.75 0.75 -0.01 0.68 0.59 0.66 
2 A
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0.98 1.00 0.05 0.94 0.04 0.99 0.56 0.93 0.03 0.80 0.76 0.76 -0.01 0.69 0.61 0.67 
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0.04 0.05 1.00 0.08 0.01 0.05 0.24 0.07 0.02 0.10 0.09 0.08 0.02 0.12 0.09 0.10 
4 A
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0.92 0.94 0.08 1.00 0.04 0.93 0.52 0.97 0.04 0.78 0.77 0.80 0.00 0.64 0.56 0.63 
5 
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0.04 0.04 0.01 0.04 1.00 0.05 0.08 0.04 0.42 0.02 0.01 0.00 0.59 0.05 0.10 0.06 
6 A
lt.
 
0.97 0.99 0.05 0.93 0.05 1.00 0.57 0.94 0.02 0.80 0.77 0.77 0.00 0.70 0.62 0.68 
7 
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0.54 0.56 0.24 0.52 0.08 0.57 1.00 0.58 0.09 0.50 0.51 0.51 0.07 0.52 0.52 0.54 
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0.92 0.93 0.07 0.97 0.04 0.94 0.58 1.00 0.04 0.79 0.79 0.81 0.00 0.66 0.60 0.65 
9 
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0.02 0.03 0.02 0.04 0.42 0.02 0.09 0.04 1.00 0.04 0.05 0.03 0.66 0.03 0.09 0.05 
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0.79 0.80 0.10 0.78 0.02 0.80 0.50 0.79 0.04 1.00 0.96 0.96 0.00 0.87 0.75 0.84 
11 
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t 
0.75 0.76 0.09 0.77 0.01 0.77 0.51 0.79 0.05 0.96 1.00 0.98 0.00 0.82 0.76 0.85 
12 A
lt.
 
0.75 0.76 0.08 0.80 0.00 0.77 0.51 0.81 0.03 0.96 0.98 1.00 -0.02 0.81 0.74 0.82 
13 
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-0.01 -0.01 0.02 0.00 0.59 0.00 0.07 0.00 0.66 0.00 0.00 -0.02 1.00 0.00 0.04 0.02 
14 A
lt.
 
0.68 0.69 0.12 0.64 0.05 0.70 0.52 0.66 0.03 0.87 0.82 0.81 0.00 1.00 0.90 0.95 
15 
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0.59 0.61 0.09 0.56 0.10 0.62 0.52 0.60 0.09 0.75 0.76 0.74 0.04 0.90 1.00 0.95 
16 A
lt.
 
0.66 0.67 0.10 0.63 0.06 0.68 0.54 0.65 0.05 0.84 0.85 0.82 0.02 0.95 0.95 1.00 
Predictive correlations 0.35 0.34 0.39 0.33 0.31 0.30 0.32 0.29 0.28 0.24 0.21 0.20 0.39 0.34 0.35 0.34 
a: Performance is measured by correlation between predicted and observed phenotype. 
b: Model-type “Best”: Model judged to be top based on performance in out-of-data prediction. 
c: Model-type ‘Alt.”: Model close in performance to top models as in (b) however also consistent 
across GO data incorporation strategy and phenotype definitions. 
Table 4: Performance measures and similarity measures for the top chosen “Alternate-model”, 
one for each phenotype definition. 
 
CDC symptom inventory Medical 
Outcomes 
Survey Short-
Form (SF-36) 
Multidimensional 
Fatigue Inventory 
(MFI) 
All 
symptoms 
CFS 
related 
symptoms 
(1) (2) (3) (4) 
Predictive correlation  0.34 0.30 .024 0.34 
      
Correlations between the 
coefficients of the GO-
term for the four chosen 
predictive models. 
(1) 1.00 0.99 0.80 0.69 
(2)  1.00 0.80 0.70 
(3)   1.00 0.87 
(4)    1.00 
      
Number of common GO-
terms with coefficients in 
top 20% for each chosen 
modelab. 
(1) 156 147 87 77 
(2)  156 89 79 
(3)   155 113 
(4)    156 
a: A maximum of 156 terms, i.e. 20% of the 781 terms considered, can occur, however a 
particular model may not use all GO-terms. 
b: 69 of these terms are common between all four models (see table-5). 
Table 5: Top pathways common among the chosen four “Alternate models” (from table-3), one 
for each phenotype. 
GO code GO Term 
GO:0007268 synaptic transmission 
GO:0055080 cation homeostasis 
GO:0030003 cellular cation homeostasis 
GO:0055066 di, tri-valent inorganic cation homeostasis 
GO:0030005 cellular di, tri-valent inorganic cation homeostasis 
GO:0055065 metal ion homeostasis 
GO:0006875 cellular metal ion homeostasis 
GO:0006874 cellular calcium ion homeostasis 
GO:0014070 response to organic cyclic substance 
GO:0043269 regulation of ion transport 
GO:0030534 adult behavior 
GO:0003001 generation of a signal involved in cell-cell signaling 
GO:0040029 regulation of gene expression, epigenetic 
GO:0007612 learning 
GO:0051271 negative regulation of cell motion 
GO:0051924 regulation of calcium ion transport 
GO:0030336 negative regulation of cell migration 
GO:0050905 neuromuscular process 
GO:0008344 adult locomotory behavior 
GO:0050769 positive regulation of neurogenesis 
GO:0006898 receptor-mediated endocytosis 
GO:0034101 erythrocyte homeostasis 
GO:0031346 positive regulation of cell projection organization 
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway 
GO:0030111 regulation of Wnt receptor signaling pathway 
GO:0030218 erythrocyte differentiation 
GO:0046324 regulation of glucose import 
GO:0010827 regulation of glucose transport 
GO:0018108 peptidyl-tyrosine phosphorylation 
GO:0000060 protein import into nucleus,  translocation 
GO:0043270 positive regulation of ion transport 
GO:0048168 regulation of neuronal synaptic plasticity 
GO:0050806 positive regulation of synaptic transmission 
GO:0045216 cell-cell junction organization 
GO:0050885 neuromuscular process controlling balance 
GO:0001936 regulation of endothelial cell proliferation 
GO:0003073 regulation of systemic arterial blood pressure 
GO:0051928 positive regulation of calcium ion transport 
GO:0021987 cerebral cortex development 
GO:0051952 regulation of amine transport 
GO:0006476 protein amino acid deacetylation 
GO:0032312 regulation of ARF GTPase activity 
GO:0001974 blood vessel remodeling 
GO:0002712 regulation of B cell mediated immunity 
GO:0002889 regulation of immunoglobulin mediated immune response 
GO code GO Term 
GO:0007628 adult walking behavior 
GO:0045814 negative regulation of gene expression, epigenetic 
GO:0016575 histone deacetylation 
GO:0006342 chromatin silencing 
GO:0032890 regulation of organic acid transport 
GO:0001975 response to amphetamine 
GO:0014073 response to tropane 
GO:0042220 response to cocaine 
GO:0033619 membrane protein proteolysis 
GO:0007622 rhythmic behavior 
GO:0035162 embryonic hemopoiesis 
GO:0042274 ribosomal small subunit biogenesis 
GO:0050853 B cell receptor signaling pathway 
GO:0045730 respiratory burst 
GO:0050974 detection of mechanical stimulus involved in sensory perception 
GO:0001963 synaptic transmission, dopaminergic 
GO:0034605 cellular response to heat 
GO:0045686 negative regulation of glial cell differentiation 
GO:0014014 negative regulation of gliogenesis 
GO:0046325 negative regulation of glucose import 
GO:0050910 detection of mechanical stimulus involved in sensory perception of sound 
GO:0018198 peptidyl-cysteine modification 
GO:0001993 regulation of systemic arterial blood pressure by norepinephrine-epinephrine 
GO:0044070 regulation of anion transport 
 
Table 6: Prediction of the binary phenotype under different schemes of functional data 
augmentation. The variable selection is done by SPCA and generalized linear model (in 
particular logistic regression) is used for predictive modeling. 
Method of estimation Prediction accuracy for GO-input level 
 Start Middle End 
Cutoff on estimated phenotype Tot-score 
 
67% 73% 71% 
Logistic regression as predictive model, with 
correlation used for variable selection 
 
70% 63% 72% 
Logistic regression as predictive model, with t-
test used for variable selection 
 
72% 65% 72% 
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1. CFS severity score based on CDC symptom inventory: As reported in Wagner et al 
(2005) the CDC symptom Inventory collected information on 19 fatigue and illness-related 
symptoms (Table-2) during the month preceding the interview. By comparing with the 
symptoms reported in the same paper, we identified 9 CFS-defining symptoms (pertaining to the 
8 symptoms mentioned therein, viz. post-exertional fatigue, un-refreshing sleep, problems 
remembering or concentrating, muscle aches and pains, joint pain, sore throat, tender lymph 
nodes and swollen glands, and headaches). The CDC inventory also includes diarrhea, fever, 
chills, sleeping problems, nausea, stomach or abdominal pain, sinus or nasal problems, shortness 
of breath, sensitivity to light, and depression. We followed the transformation of frequency and 
severity as suggested in literature. Let, 
N: Number of subjects in the study 
Xi: the score for i-th subject, i =1, …, N 
M: the number of symptoms in a particular data collection method, 8 for SF36, 5 for 
MDF and 19 for CDC inventory (with details presented in table-2). 
Sij: severity of j-th symptom of the i-th subject and was measured on a three-point 
scale (1 = mild, 2 = moderate, 3 = severe), i=1, …, N, j= 1, …, M,  
fij: frequency of the j-th symptom of the i-th subject and was rated on a four-point 
scale (1 = a little of the time, 2 = some of the time, 3 = most of time, 4 = all of the time), i=1, …, 
N, j= 1, …, M. 
Then for the i-th individual the symptom score is obtained using ∑
=
=
M
j
ijiji fSX
1
. As 
reported in Reeves et al (2005) the intensity scores were transformed into equidistant scores 
before multiplication (i.e., 0 = symptom not reported 1 = mild, 2.5 = moderate, 4 = severe). 
We propose to use the total symptom scores consisting of all the symptoms mentioned in 
Table-2 above. Additionally, based on the 9 symptoms that are more focused to CFS, another 
symptom scores will also be modeled. We will denote the overall score as “Tot-score” and the 
score based on subset of symptoms as ‘CFS-score”. In addition to these the SF36 and MDF 
scores (mentioned above) would also be used occasionally. 
2. Principal component analysis: PCA is a method of transforming the original variables 
into new uncorrelated variables which are weighted averages of the original variables. Suppose 
X1, X2, … ,  Xp  are p variables of interest. The first principal component Y1, is defined as a linear 
combination  
Y1 = a1' X = a11 X1 + a12 X2 + … + a1p Xp 
where, X = (X1, X2, … , Xp)' and a1'= (a11 , a12 , … , a1p ).  Vector a1 is chosen so as to 
maximize the variance of Y1 subject to the constraint a1' a1= 1. The second principal component 
Y2 is a linear combination  
Y2 = a2' X = a21X1 + a22X2 + … + a2pXp, 
which has the greatest variance subject to two conditions: a2' a2 = 1 and a2' a1 = 0.  
The second condition ensures that Y1 and Y2 are uncorrelated. Continuing on similar lines, 
the j-th principal component is defined. Thus, in finding principal components we are faced with 
the problem of maximizing a function of several variables subject to one or more constraints. 
Using the method of Lagrange's multipliers it is proved that Var(Y1) is maximized subject to the 
condition  when a1 is the eigen vector of S corresponding to the largest eigen value of S, where S 
is the dispersion matrix of  vector X. Thus, in general, Yj = e'jX is the j-th principal component, 
where ej is the eigen vector corresponding to the j-th largest eigen value, j =1, 2, …, p.  
In this paper, vector X is the vector of expression values of p genes. The data on gene 
expression values for N patients are available. If M denotes the N x p matrix of gene expression 
values then principal component can be obtained using the singular value decomposition of 
matrix M (Jolliffe, 2002). 
3. Supervised principal component analysis: SPCA is PCA applied on the select set of 
genes, selected on the basis of association of the genes with the outcome variable (Paul et al. 
2008). For example, the genes which are highly correlated with the outcome constitute the select 
set of genes, secondly the genes may be grouped using gene ontology information, or genes in 
the same pathway, or genes involved in the same cellular process.  Since the set of genes is 
formed using outcome information the procedure is known as supervised procedure. 
4. Linear model: In a linear model  a variable Y, which  is a response  to k factors  U1, U2, 
…, Uk, is modeled as  Y = β0 +β1U1 +… +βkUk + ε. The parameters β0 , β1 ,… ,βk  are known as 
regression coefficients and ε is the random error, assumed to be normally distributed. The 
regression coefficients are determined so that the residual sum of squares is minimum. The aim 
of the analysis is to find out the factors which affect response variable significantly. In this paper 
response variable is disease score (total or CFS), thus Yj denotes the response of the j-th patient. 
It may be survival time or any continuous phenotype score, j = 1, 2,…, N. The factors may be  
the gene expression values or the first few PC’s of gene expression values or these may be PC’s 
corresponding to genes in the select group, selected according certain criteria. We have adopted 
the latter approach in this paper.  
5. Cross validation: Cross validation is a method to evaluate the model, by segmenting the 
data into training and test sets. In k-fold validation the data are segmented into k sets. 
Subsequently,  k iterations of training and validation are performed such that within each 
iteration a different fold of the data is held out for validation while the remaining k-1 are used for 
training or building the model. 
 
 
